#ASH17: Sy­ros evis­cer­at­ed by in­vestor back­lash as lead drug flails bad­ly in PhII

It didn’t take long Mon­day morn­ing to see who the worst per­former for the ASH week­end would be. Sy­ros $SYRS cratered quick­ly once in­vestors got a chance to re­spond to the hard ev­i­dence that their lead drug is fail­ing bad­ly in a Phase II study.

It’s hard to tell from the re­lease, which fo­cused a lot of en­er­gy on ev­i­dence of clin­i­cal ac­tiv­i­ty, but the pri­ma­ry end­points in the study had to do with over­all re­sponse rates for acute myeloid leukemia as well as trans­fu­sion in­de­pen­dence in myelodys­plas­tic syn­drome.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.